Quick Answer
TriSalus Life Sciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $20.44 million for the year ending 2025.
- TriSalus Life Sciences, Inc. showed an increase of +139.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from TriSalus Life Sciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.13 million | Q2 2021: $642.9 thousand | Q3 2021: $277.8 thousand | Q1 2022: $50.9 thousand | Q2 2022: $69.2 thousand | Q3 2022: $207.6 thousand | Q1 2023: $136.8 thousand | Q2 2023: $104.0 thousand | Q3 2023: $21.38 million | Q1 2024: $3.97 million | Q2 2024: $16.48 million | Q3 2024: $11.29 million | Q1 2025: $13.00 million | Q2 2025: $26.49 million | Q3 2025: $22.69 million.
- Over the full 6 years of available data (2020 to 2025), TriSalus Life Sciences, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,431.0%.
- Historical annual values: Fiscal year 2025: $20.44 million | Fiscal year 2024: $8.53 million | Fiscal year 2023: $11.78 million | Fiscal year 2022: $9.41 million | Fiscal year 2021: $200.9 thousand | Fiscal year 2020: $1.33 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: